Bruker (NASDAQ:BRKR) PT Raised to $74.00 at The Goldman Sachs Group

Bruker (NASDAQ:BRKR) had its price target upped by equities research analysts at The Goldman Sachs Group from $66.00 to $74.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a “sell” rating on the medical research company’s stock. The Goldman Sachs Group’s target price would indicate a potential downside of 18.03% from the company’s current price.

A number of other brokerages have also weighed in on BRKR. UBS Group lifted their price objective on Bruker from $94.00 to $102.00 and gave the company a “buy” rating in a report on Friday, March 1st. Citigroup lifted their price objective on Bruker from $80.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. Wolfe Research began coverage on Bruker in a report on Wednesday, December 13th. They issued an “outperform” rating and a $80.00 price objective on the stock. Wells Fargo & Company began coverage on Bruker in a report on Tuesday, December 19th. They issued an “equal weight” rating and a $72.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised Bruker from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $60.00 to $90.00 in a report on Wednesday, February 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.86.

Bruker Stock Performance

NASDAQ BRKR opened at $90.28 on Wednesday. The company has a quick ratio of 0.99, a current ratio of 1.80 and a debt-to-equity ratio of 0.83. Bruker has a 52-week low of $53.79 and a 52-week high of $94.86. The business’s 50-day moving average price is $86.45 and its 200 day moving average price is $73.11. The firm has a market cap of $12.43 billion, a P/E ratio of 30.92, a P/E/G ratio of 2.29 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, February 13th. The medical research company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Bruker had a return on equity of 29.94% and a net margin of 14.41%. The company had revenue of $844.50 million for the quarter, compared to analyst estimates of $809.35 million. During the same quarter in the previous year, the company earned $0.74 EPS. The firm’s revenue for the quarter was up 19.2% compared to the same quarter last year. On average, equities research analysts expect that Bruker will post 2.74 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Hermann Fritz Requardt sold 15,000 shares of Bruker stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the completion of the transaction, the director now directly owns 23,147 shares in the company, valued at approximately $2,084,618.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 28.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of BRKR. Farther Finance Advisors LLC raised its holdings in Bruker by 90.4% in the 2nd quarter. Farther Finance Advisors LLC now owns 356 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 169 shares during the last quarter. Lindbrook Capital LLC raised its holdings in Bruker by 68.2% in the 4th quarter. Lindbrook Capital LLC now owns 360 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 146 shares during the last quarter. Zions Bancorporation N.A. acquired a new position in Bruker in the 1st quarter valued at $26,000. Rise Advisors LLC acquired a new position in Bruker in the 1st quarter valued at $27,000. Finally, Altshuler Shaham Ltd purchased a new stake in shares of Bruker during the 4th quarter valued at $27,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.